An observational study in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis and Advanced Fibrosis, sponsored by Linkoeping University. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Linkoeping University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Sarcopenia with a site in Sweden — 6 open to participants now, 6 under way, none of them phase 3. Sarcopenia · Sweden.
Among the 10 studies in Sarcopenia with a site in Sweden, this one is one of 3 that started in 2025, is one of 8 observational ones, and was the 10th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →6 of the 10 studies in Sarcopenia with a site in Sweden are open now. Recruiting first, the newest first:
Mattias Ekstedt · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+
Sahlgrenska University Hospital · Sites in Sweden
Ages 18+
Linkoeping University · Sites in Sweden
Ages 18+
The Swedish School of Sport and Health Sciences · Sites in Sweden
Ages 18–80
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 317 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 180 across the 2 interventional studies, 165 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Linkoeping University is the lead sponsor of 193 studies on the registry; 40 are open to participants now.
Linkoeping University has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Sarcopenia with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06300541Sahlgrenska University HospitalPrevalence and Impact of Sarcopenia in Patients With Inflammatory Bowel Disease | 2027-05-01 |
| NCT06687291Karolinska InstitutetCognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Sarcopenia with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
The main questions it aims to answer are:
Participants will:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases worldwide and is particularly common among individuals with type 2 diabetes. While many people remain stable over time, some develop progressive liver fibrosis, cirrhosis, hepatocellular carcinoma, and other serious liver-related complications. Reliable methods for identifying patients at greatest risk of disease progression remain limited.
EPSOMIP2 is a prospective observational follow-up study of participants who were previously enrolled in the EPSONIP study (NCT03864510) between 2019 and 2023. In the original study, 317 individuals with type 2 diabetes from primary healthcare centers in Östergötland, Sweden, underwent detailed evaluation of liver disease, metabolic health, physical activity, and body composition.
Participants who completed the original study are invited to undergo a new assessment approximately 6 years after their initial evaluation. The follow-up examination includes clinical assessment, blood and urine sampling, vibration-controlled transient elastography, magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), magnetic resonance elastography (MRE), body composition analysis, questionnaires, physical activity measurements, blood pressure assessments, and biobanking.
By comparing the follow-up findings with data collected during the original EPSONIP study, researchers aim to characterize the long-term natural history of MASLD in type 2 diabetes. The study will evaluate prevalence, progression, and regression of hepatic steatosis and liver fibrosis, and investigate associations with physical activity, body composition, genetic variants, hypertension, obstructive sleep apnea, and other metabolic risk factors.
The study will also investigate the occurrence of clinically significant liver-related outcomes, including decompensated liver disease, hepatocellular carcinoma, liver transplantation, and liver-related mortality. In addition, health-economic analyses will be performed to evaluate strategies for MASLD management and risk stratification.
The overall aim of EPSOMIP2 is to improve understanding of the long-term course of MASLD in individuals with type 2 diabetes and to identify factors associated with progression to advanced liver disease.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
This study's planned enrollment of 317 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Browse Sarcopenia studies →Linkoeping University is the lead sponsor of 193 studies on the registry; 40 are open to participants now.
Compared within Sarcopenia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 9, 2026. See what changed
Patients who where previously included, and completed the assessments in the EPSONIP study (NCT03864510) between 2019 and 2023 are re-invited to fulfill the same evaluation with additional tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevalence of MASLD (MRI-PDFF)
Number of patients with MASLD measured with MRI-PDFF
Time frame: From December 2025 to December 2031
Prevalence of MASLD (CAP)
Number of patients with MASLD measured with CAP
Time frame: From December 2025 to December 2031
Progression/regression of MASLD (MRI-PDFF)
Number of patients who progress/regress to/from MASLD between two timepoints as measured with MRI-PDFF
Time frame: From December 2025 to December 2031
Progression/regression of MASLD (CAP)
Number of patients who progress/regress to/from MASLD between two timepoints as measured with CAP
Time frame: From December 2025 to December 2031
Prevalence of advanced fibrosis (VCTE)
Number of patients with advanced liver disease as defined by VCTE
Time frame: From December 2025 to December 2031
Prevalence of advanced fibrosis (MRE)
Number of patients with advanced liver disease as defined by MRE
Time frame: From December 2025 to December 2031
Prevalence of advanced fibrosis (Clinical signs)
Number of patients with advanced liver disease as defined by clinical signs of decompensation
Time frame: From December 2025 to December 2031
Progression/regression of advanced fibrosis (VCTE)
Progression/regression to/from advanced liver disease as measured with VCTE between two timepoints
Time frame: From December 2025 to December 2031
Progression/regression of advanced fibrosis (MRE)
Progression/regression to/from advanced liver disease as measured with MRE between two timepoints
Time frame: From December 2025 to December 2031
The association between physical activity (IFIS) and prevalent advanced fibrosis
Liver fibrosis measured according to the primary outcome definitions described above. Physical activity measured with the international fitness scale (IFIS).
Time frame: From December 2025 to December 2031
The association between physical activity (Actigraph GT3X) and prevalent advanced fibrosis
Liver fibrosis measured according to the primary outcome definitions described above. Physical activity measured with Actigraph GT3X (accelerometer).
Time frame: From December 2025 to December 2031
The association between physical activity (IFIS) and risk of progressing to advanced fibrosis
Liver fibrosis progression measured according to the primary outcome definitions described above. Physical activity measured with the international fitness scale (IFIS).
Time frame: From December 2025 to December 2031
The association between physical activity (Actigraph GT3X) and risk of progressing to advanced fibrosis
Liver fibrosis progression measured according to the primary outcome definitions described above. Physical activity measured with Actigraph GT3X (accelerometer).
Time frame: From December 2025 to December 2031
Genetic factors associated with advanced fibrosis or MASLD progression/regression
Liver fibrosis and fat measured according to the primary outcome definitions described above. Genes to be analyzed: PNPLA3, TM6SF2, MBOAT7 among others.
Time frame: From December 2025 to December 2031
Association between body composition and MASLD and/or liver fibrosis and progression/regression thereof
Liver fibrosis and fat measured according to the primary outcome definitions described above. Body composition measured with AMRA Medical AB's MAsS Scan.
Time frame: From December 2025 to December 2031
The association of hypertension (weekly blood pressure monitoring) and MASLD with or without signs of advanced fibrosis
Liver fibrosis and fat measured according to the primary outcome definitions described above. Hypertension measured with weekly blood pressure monitoring.
Time frame: From December 2025 to December 2031
The association of hypertension (24-hour ambulatory blood pressure monitoring) and MASLD with or without signs of advanced fibrosis
Liver fibrosis and fat measured according to the primary outcome definitions described above. Hypertension measured with 24-hour ambulatory blood pressure monitoring.
Time frame: From December 2025 to December 2031
The association between OSAS and MASLD with or without advanced fibrosis
Liver fibrosis and fat measured according to the primary outcome definitions described above. OSAS measured at university hospital sleep apnea clinic.
Time frame: From December 2025 to December 2031
Health economic model for disease management
Markov modelling.
Time frame: From January 2028 to December 2034
Number of patients that develop symptoms of end-stage liver disease
Symptoms of end-stage liver disease (e.g., ascites, encephalopathy, varices, HCC) or liver-related death will be recorded through chart review
Time frame: From December 2025 to December 2034
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2031, 72 months after the start.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 72 months is above that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.